In reaction to strong earnings/guidance: RHT +10.6%, PIR +7.9%, CTAS +7.3%.
M&A related: APP +4% (following late spike higher following NYPost report of takeover offer valuing company at $1.30-1.40/share), XRX +3.7% (Atos to acquire Xerox's information technology outsourcing business for $1.05 bln; does not anticipate earnings per share dilution beyond 2015; updates Q4 and FY15 guidance to reflect acquisition), CBST +1.3% (Merck (MRK) begins tender offer to acquire Cubist for $102.00 per share in cash), UTIW +0.8% (responds to Bloomberg report that UTIW is in 'advanced talks' to sell itself to DSV; UTIW states that those discussions never progress beyond a preliminary stage) .
A few Brazil names are trading higher: BRFS +3.9%, PBR +2.2% EBR +2.5%, CBD +1.5%
Other news: PETX +26.2% (announced positive top-line results from AT-001 pivotal field study in client-owned dogs with osteoarthritis), MOLG +13.7% (announces commencement of share repurchase program), CERS +13.6% (FDA approves intercept blood system for platelets), ISIS +7.1% (among stocks with favorable commentary on Thursday's Mad Money), MSG +4.6% (authorized and directed mgmt also to consider other spin-off structures including separation of the media business from its sports and entertainment businesses), KEG +3.7% (after 35% move higher yesterday), ALLY +3.3% (files for offering of common stock, size not disclosed; U.S. Department of Treasury launched offering to sell its remaining ~54.9 mln shares of Ally common stock), OREX+3.3% (confirms that the Committee for Medicinal Products For Human Use of the European Medicines Agency has adopted a positive opinion recommending the granting of a centralized marketing authorization for Mysimba), OGXI +3.1% (nnounced results from the randomized, controlled Phase 2 Borealis-1 trial evaluating low and high dose apatorsen in combination with gemcitabine/cisplatin chemotherapy compared to chemotherapy alone in the treatment of metastatic bladder cancer), RCAP +2.5% (following yesterday's 15%+ move lower following ARCP news; issues statement regarding recent market developments; says 'here have been no reported accounting irregularities at RCS Capital'), MBT +2.5%/ VIP +1% (Mobile TeleSystems partnered with VimpelCom to jointly roll-out and utilize LTE networks in 36 Russian regions), SIMG +2.4% (after 30% move lower yesterday), FRO +2.3% (cont strength), Q +1.9% (among stocks with favorable commentary on Thursday's Mad Money), TICC +1.3% (adopts stock repurchase program of up to $50 mln worth of common shares), PTCT +1.1% (Translarna Granted Orphan Drug Designation in the U.S. and Europe for the Treatment of Mucopolysaccharidosis), CQP +0.7% (Cheniere and GE Sign $1B Service Agreement for Sabine Pass LNG Export Terminal), NRZ +0.7% (increases quarterly dividend), GILD +0.4% (Gilead Sciences and Ono Pharma (OPHLY) announced that the companies have entered into an exclusive license agreement for the development and commercialization of ONO-4059), KO +0.3% (Coca-Cola Bottling Co. announces agreement with Coca-Cola to expand franchise territory).
Analyst comments: POT +1.8% (upgraded to Buy from Neutral at UBS; tgt raised to $40 from $38), ORAN +1.1% (upgraded to Buy from Hold at Deutsche Bank), RYAAY +1% (upgraded to Outperform from In-line at Imperial Capital; tgt raised to $85 from $60), IRBT +0.7% (initiated with Overweight and $42 target at Piper Jaffray),-hammer and fly after TWTR +0.7% (initiated with Perform at Opco; tgt $36), MPW +0.6% (upgraded to Hold from Underweight at KeyBanc Capital Mkts), AAPL +0.3% (positive Morgan Stanley comments related to iPhone demand
)
M&A related: APP +4% (following late spike higher following NYPost report of takeover offer valuing company at $1.30-1.40/share), XRX +3.7% (Atos to acquire Xerox's information technology outsourcing business for $1.05 bln; does not anticipate earnings per share dilution beyond 2015; updates Q4 and FY15 guidance to reflect acquisition), CBST +1.3% (Merck (MRK) begins tender offer to acquire Cubist for $102.00 per share in cash), UTIW +0.8% (responds to Bloomberg report that UTIW is in 'advanced talks' to sell itself to DSV; UTIW states that those discussions never progress beyond a preliminary stage) .
A few Brazil names are trading higher: BRFS +3.9%, PBR +2.2% EBR +2.5%, CBD +1.5%
Other news: PETX +26.2% (announced positive top-line results from AT-001 pivotal field study in client-owned dogs with osteoarthritis), MOLG +13.7% (announces commencement of share repurchase program), CERS +13.6% (FDA approves intercept blood system for platelets), ISIS +7.1% (among stocks with favorable commentary on Thursday's Mad Money), MSG +4.6% (authorized and directed mgmt also to consider other spin-off structures including separation of the media business from its sports and entertainment businesses), KEG +3.7% (after 35% move higher yesterday), ALLY +3.3% (files for offering of common stock, size not disclosed; U.S. Department of Treasury launched offering to sell its remaining ~54.9 mln shares of Ally common stock), OREX+3.3% (confirms that the Committee for Medicinal Products For Human Use of the European Medicines Agency has adopted a positive opinion recommending the granting of a centralized marketing authorization for Mysimba), OGXI +3.1% (nnounced results from the randomized, controlled Phase 2 Borealis-1 trial evaluating low and high dose apatorsen in combination with gemcitabine/cisplatin chemotherapy compared to chemotherapy alone in the treatment of metastatic bladder cancer), RCAP +2.5% (following yesterday's 15%+ move lower following ARCP news; issues statement regarding recent market developments; says 'here have been no reported accounting irregularities at RCS Capital'), MBT +2.5%/ VIP +1% (Mobile TeleSystems partnered with VimpelCom to jointly roll-out and utilize LTE networks in 36 Russian regions), SIMG +2.4% (after 30% move lower yesterday), FRO +2.3% (cont strength), Q +1.9% (among stocks with favorable commentary on Thursday's Mad Money), TICC +1.3% (adopts stock repurchase program of up to $50 mln worth of common shares), PTCT +1.1% (Translarna Granted Orphan Drug Designation in the U.S. and Europe for the Treatment of Mucopolysaccharidosis), CQP +0.7% (Cheniere and GE Sign $1B Service Agreement for Sabine Pass LNG Export Terminal), NRZ +0.7% (increases quarterly dividend), GILD +0.4% (Gilead Sciences and Ono Pharma (OPHLY) announced that the companies have entered into an exclusive license agreement for the development and commercialization of ONO-4059), KO +0.3% (Coca-Cola Bottling Co. announces agreement with Coca-Cola to expand franchise territory).
Analyst comments: POT +1.8% (upgraded to Buy from Neutral at UBS; tgt raised to $40 from $38), ORAN +1.1% (upgraded to Buy from Hold at Deutsche Bank), RYAAY +1% (upgraded to Outperform from In-line at Imperial Capital; tgt raised to $85 from $60), IRBT +0.7% (initiated with Overweight and $42 target at Piper Jaffray),-hammer and fly after TWTR +0.7% (initiated with Perform at Opco; tgt $36), MPW +0.6% (upgraded to Hold from Underweight at KeyBanc Capital Mkts), AAPL +0.3% (positive Morgan Stanley comments related to iPhone demand
)